Navigation Links
Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Date:11/2/2011

LA JOLLA, Calif., Nov. 2, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the Australian Patent Office has recently granted claims in the 'Sarnow' patent series for microRNA-122 (miR-122) therapy in the treatment of hepatitis C viral (HCV) infections. The granted claims in Australia extend the reach of the Sarnow patent estate that already covers the use of an anti-miR inhibitor of miR-122 for the treatment of HCV in the United States and Europe. The Sarnow patent series, owned by Stanford University, has been exclusively licensed to Regulus and covers any compound that targets miR-122 for the treatment of HCV in the United States, Europe, and Australia.  

Regulus controls a comprehensive and dominant patent estate related to microRNA therapeutics, including miR-122 therapeutic agents. Specifically for miR-122, Regulus controls the following:

  • The 'Sarnow' patent estate claiming the use of anti-miR-122 to treat HCV infection, as a single therapeutic agent or in combination with other HCV therapeutic agents (US Patent No. 7,307,067; US Patent No. 7,838,504; EP Patent No. 1 747 023; and Australian Patent Application No. 2005240118 recently accepted for grant);
  • The 'Esau' patent claiming the use of anti-miRs targeting miR-122 as inhibitory agents (US Patent No. 7,683,036);
  • The 'Tuschl III' patent claiming compositions of matter for miR-122 and complementary oligonucleotides (US Patent No. 7,232,806);
  • The 'Manoharan' patent claiming antagomirs, including antagomirs targeting miR-122 (US Patent No. 7,582,744); and
  • A Regulus-owned European patent claiming the use of miR-122 antagonists for reducing cholesterol (EP 1 931 782).

"We are pleased with the recent allowance of miR-122 claims in Au
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
4. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Amgen (Nasdaq: AMGN ) today announced the ... of 1,776 advanced cancer patients with different types of ... multiple myeloma, which compared XGEVA ™ (denosumab) to ... study, which appeared today in the Journal of ...
... drugstore.com, inc. (Nasdaq: DSCM ), ... skincare, and vision products, today announced that the ... events with the financial community: (Logo: ... Telecom Conference Date: February 28, 2011Time: 3:20 p.m. ...
Cached Medicine Technology:The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8drugstore.com to Present at Upcoming Financial Conferences 2
(Date:7/9/2014)... in Western societies. One frequently cited reason is that ... infections than previous generations, thereby delaying maturation of the ... Academy, University of Gothenburg, monitored children until the age ... in relation to allergic disease. All of the children ... half of them on farms that produced milk.,Lower risk ...
(Date:7/8/2014)... kidney donors enjoy similar longevity and cardiovascular health as ... published in the American Journal of Transplantation . ... considering donation and the transplant professionals caring for them. ... by individuals aged 55 years and older has become ... disease, and heart disease, the removal of a kidney ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
(Date:7/8/2014)... were found to be three times higher when auditors ... no auditors present, according to a study in a ... titled, "Quantification of the Hawthorne effect in hand hygiene ... cohort study," published today on-line in the BMJ ... Jocelyn Srigley, who did the study as part of ...
(Date:7/8/2014)... University of Iowa researchers have discovered a biomarker that ... simple blood test to reliably predict that a pregnant ... 6 weeks into the pregnancy. , Preeclampsia is a ... resulting in an early delivery, creating immediate and potentially ... high blood pressure and protein in the urine, and ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... Calif., Sept. 4 Martin Schiff, M.D.,is an illustrious ... and weight loss. His career is detailed in "Who,s ... in America," "Who,s Who in,the World," "Who,s Who in ... Dr. Schiff recently retired to devote his expertise to ...
... ONGAR, Ireland,Sept. 4 Schofield Publishing, a division of ... it has acquired Health and,Safety Monitor publication from Silverdog ... the same time as the iconic,Health and Safety at ... then. It has been relied upon by blue-chip corporates,independent ...
... New Educational Program Kicks Off September,s Ovarian Cancer Awareness ... ... Today the National Ovarian Cancer,Coalition (NOCC) launched its newest educational initiative, Eva,s ... family who will be the first to pledge to empower and educate,women ...
... ULURU Inc. (Amex:,ULU) today announced that it is ... Conference at 3:15 p.m. Eastern Time on Thursday,September ... Inc. is an emerging specialty pharmaceutical company focused ... plastic surgery and,oral care products to provide patients ...
... YORK, Sept. 4 Come fall, women are always in ... and fit into their favorite,jeans that have become a little ... how women can look celeb-good in their,jeans and how they ... helping the United Way., (See video from Kellogg,s ...
... In some countries, lime juice is,thought to ward ... Against such a backdrop of misinformation and stigma, how ... tens of millions,of people?, Part of the answer ... media, says,Internews Network, an international media development nonprofit that ...
Cached Medicine News:Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:Schofield Publishing Enters the Newsletter Market 2Health News:National Ovarian Cancer Coalition and CSI: Miami Star Eva La Rue Launch Eva's Divas in Hollywood to Educate Women Nationwide About Ovarian Cancer 2Health News:National Ovarian Cancer Coalition and CSI: Miami Star Eva La Rue Launch Eva's Divas in Hollywood to Educate Women Nationwide About Ovarian Cancer 3Health News:More than 1,000 Journalists Enlisted in Fight Against HIV/AIDS 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: